TREE NEWS update: China’s drug regulator has conditionally approved Aipuswei (hydrochloride istevir), a COVID-19 treatment for adults with mild-to-moderate infection, developed by Westlake University, Westlake Laboratory, and Westlake Pharmaceuticals. It is China’s first original drug developed with AI assistance, from discovery to clinical trial completion in just three and a half years.
China Approves First AI-Assisted Developed Drug
AI take
This approval marks a regulatory milestone for AI-driven drug development, signaling that AI-assisted discovery can move from lab to market within a compressed timeline. It affects both the domestic pharma ecosystem and global observers tracking whether AI can reliably shorten R&D cycles beyond this specific case. The open question is whether this conditional approval sets a precedent for broader AI-assisted therapeutics, or remains an isolated breakthrough given the unique pressures of pandemic-related development.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
8h ago
Westlake University Launches World Model Research Center
8h ago
DeepSeek open-sources Personal Agent architecture
8h ago
What Is AI Reward Hacking and Why It Matters
8h ago
2026 World Internet of Things Expo opens in Wuxi
10h ago
xAI’s Grok Adds UnionPay and Alipay Payment Support in Mainland China
12h ago
SK Group Chairman Choi Tae-won Meets OpenAI CEO Sam Altman Over Lunch